Clinical Impact of Oral Intake in Second-line or Third-line Chemotherapy for 589 Patients With Advanced Gastric Cancer: A Retrospective Cohort Study.

Takatsugu Ogata, Yukiya Narita, Ryosuke Kumanishi, Taiko Nakazawa, Yuki Matsubara, Kyoko Kato, Kazuki Nozawa, Kazunori Honda, Toshiki Masuishi, Hideaki Bando, Shigenori Kadowaki, Masashi Ando, Masahiro Tajika, Kei Muro
{"title":"Clinical Impact of Oral Intake in Second-line or Third-line Chemotherapy for 589 Patients With Advanced Gastric Cancer: A Retrospective Cohort Study.","authors":"Takatsugu Ogata,&nbsp;Yukiya Narita,&nbsp;Ryosuke Kumanishi,&nbsp;Taiko Nakazawa,&nbsp;Yuki Matsubara,&nbsp;Kyoko Kato,&nbsp;Kazuki Nozawa,&nbsp;Kazunori Honda,&nbsp;Toshiki Masuishi,&nbsp;Hideaki Bando,&nbsp;Shigenori Kadowaki,&nbsp;Masashi Ando,&nbsp;Masahiro Tajika,&nbsp;Kei Muro","doi":"10.1097/COC.0000000000000835","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Insufficient oral intake in advanced gastric cancer (AGC) limits the use of several drugs. We aimed to determine the oral intake status of patients with AGC during later-line chemotherapy.</p><p><strong>Materials and methods: </strong>We retrospectively evaluated data of patients with AGC who experienced disease progression during first-line chemotherapy administered from January 2012 to December 2018 in a single institution. We defined \"insufficient oral intake\" as requiring daily intravenous fluids or hyperalimentation. Multivariate logistic regression was performed to identify oral intake-related factors.</p><p><strong>Results: </strong>Among 589 included patients, at disease progression during first-line, second-line, and third-line chemotherapy, 78.3% (461), 53.3% (314), and 30.4% (179) of patients, respectively, exhibited sufficient oral intake. Fourth-line chemotherapy was initiated for 22.2% (131) of patients, with 20.0% (118) exhibiting sufficient oral intake. During second-line and third-line chemotherapy, 11/67 (16%) and 2/39 (5%) patients, respectively, exhibited improvements in oral intake; 85/428 (19.9%) and 70/259 (27.0%), respectively, exhibited deteriorations in oral intake. Factors correlated to deterioration in oral intake during second-line chemotherapy were poor Eastern Cooperative Oncology Group Performance Status (odds ratio, 4.32; P<0.001), moderate or severe ascites (1.96; P=0.045), peritoneal metastasis (2.12; P=0.029), prior palliative surgery (3.41; P=0.003), and high neutrophil-to-lymphocyte ratio (3.09; P<0.001); those correlated to deterioration in oral intake during third-line chemotherapy were poorly differentiated pathology (2.52; P=0.025) and high neutrophil-to-lymphocyte ratio (2.65; P=0.006).</p><p><strong>Conclusion: </strong>As later-line chemotherapy is ineffective in improving oral intake in patients with AGC, careful adaptation of regimens is required for patients at risk for impaired oral intake.</p>","PeriodicalId":501816,"journal":{"name":"American Journal of Clinical Oncology","volume":" ","pages":"388-394"},"PeriodicalIF":0.0000,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000000835","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Objectives: Insufficient oral intake in advanced gastric cancer (AGC) limits the use of several drugs. We aimed to determine the oral intake status of patients with AGC during later-line chemotherapy.

Materials and methods: We retrospectively evaluated data of patients with AGC who experienced disease progression during first-line chemotherapy administered from January 2012 to December 2018 in a single institution. We defined "insufficient oral intake" as requiring daily intravenous fluids or hyperalimentation. Multivariate logistic regression was performed to identify oral intake-related factors.

Results: Among 589 included patients, at disease progression during first-line, second-line, and third-line chemotherapy, 78.3% (461), 53.3% (314), and 30.4% (179) of patients, respectively, exhibited sufficient oral intake. Fourth-line chemotherapy was initiated for 22.2% (131) of patients, with 20.0% (118) exhibiting sufficient oral intake. During second-line and third-line chemotherapy, 11/67 (16%) and 2/39 (5%) patients, respectively, exhibited improvements in oral intake; 85/428 (19.9%) and 70/259 (27.0%), respectively, exhibited deteriorations in oral intake. Factors correlated to deterioration in oral intake during second-line chemotherapy were poor Eastern Cooperative Oncology Group Performance Status (odds ratio, 4.32; P<0.001), moderate or severe ascites (1.96; P=0.045), peritoneal metastasis (2.12; P=0.029), prior palliative surgery (3.41; P=0.003), and high neutrophil-to-lymphocyte ratio (3.09; P<0.001); those correlated to deterioration in oral intake during third-line chemotherapy were poorly differentiated pathology (2.52; P=0.025) and high neutrophil-to-lymphocyte ratio (2.65; P=0.006).

Conclusion: As later-line chemotherapy is ineffective in improving oral intake in patients with AGC, careful adaptation of regimens is required for patients at risk for impaired oral intake.

589例晚期胃癌患者口服二线或三线化疗的临床影响:回顾性队列研究
目的:晚期胃癌(AGC)患者口服摄入不足限制了几种药物的使用。我们的目的是确定晚期化疗期间AGC患者的口服摄入状况。材料和方法:我们回顾性评估了2012年1月至2018年12月在单一机构接受一线化疗期间出现疾病进展的AGC患者的数据。我们将“口服摄入不足”定义为需要每日静脉输液或高营养。采用多因素logistic回归分析确定口服摄入相关因素。结果:在589例纳入的患者中,在一线、二线和三线化疗期间疾病进展时,分别有78.3%(461)、53.3%(314)和30.4%(179)的患者表现出足够的口服摄入量。22.2%(131)的患者开始了第四线化疗,20.0%(118)的患者表现出足够的口服摄入量。在二线和三线化疗期间,分别有11/67(16%)和2/39(5%)的患者表现出口服摄入的改善;分别为85/428(19.9%)和70/259(27.0%)。与二线化疗期间口服摄入恶化相关的因素有:东部肿瘤合作组表现状况不佳(优势比,4.32;结论:由于晚期化疗对改善AGC患者的口服摄入无效,对于有口服摄入受损风险的患者,需要谨慎调整方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信